Emerging Links between Nonalcoholic Fatty Liver Disease and Neurodegeneration
暂无分享,去创建一个
[1] Zhiyong Zhou,et al. Non‐alcoholic fatty liver disease and the risk of dementia , 2022, Liver international (Print).
[2] R. Swerdlow,et al. Mitochondrial function and Aβ in Alzheimer's disease postmortem brain , 2022, Neurobiology of Disease.
[3] Sang Min Park,et al. Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults , 2022, Clinical and molecular hepatology.
[4] Elena Simona Micu,et al. Systemic and adipose tissue inflammation in NASH: correlations with histopathological aspects , 2021, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[5] L. Velloso,et al. Hippocampal Function Is Impaired by a Short-Term High-Fat Diet in Mice: Increased Blood–Brain Barrier Permeability and Neuroinflammation as Triggering Events , 2021, Frontiers in Neuroscience.
[6] E. D. Khilazheva,et al. NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer’s Disease , 2021, International journal of molecular sciences.
[7] B. Honoré,et al. Shotgun-based proteomics of extracellular vesicles in Alzheimer’s disease reveals biomarkers involved in immunological and coagulation pathways , 2021, Scientific Reports.
[8] P. Iozzo,et al. Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease , 2021, World journal of gastroenterology.
[9] R. Goyal,et al. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD , 2021, Inflammopharmacology.
[10] B. Železná,et al. Aging and high-fat diet feeding lead to peripheral insulin resistance and sex-dependent changes in brain of mouse model of tau pathology THY-Tau22 , 2021, Journal of Neuroinflammation.
[11] J. Ali,et al. Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1−42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease , 2021, Neuropharmacology.
[12] F. Crews,et al. TRAIL Mediates Neuronal Death in AUD: A Link between Neuroinflammation and Neurodegeneration , 2021, International journal of molecular sciences.
[13] H. Vilstrup,et al. Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease—Current Knowledge, Mechanisms and Perspectives , 2021, Journal of clinical medicine.
[14] F. Fu,et al. Escin ameliorates the impairments of neurological function and blood brain barrier by inhibiting systemic inflammation in intracerebral hemorrhagic mice , 2020, Experimental Neurology.
[15] R. Hultcrantz,et al. Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction , 2020, JHEP reports : innovation in hepatology.
[16] Divya P Kumar,et al. Extracellular Vesicles as Inflammatory Drivers in NAFLD , 2021, Frontiers in Immunology.
[17] C. Glass,et al. Epigenetic Regulation of Kupffer Cell Function in Health and Disease , 2021, Frontiers in Immunology.
[18] P. Gual,et al. Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies , 2020, Frontiers in Endocrinology.
[19] M. Calzada,et al. Time-dependent dual effect of NLRP3 inflammasome in brain ischemia , 2020, bioRxiv.
[20] M. Selenica,et al. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model , 2020, Journal of Neuroinflammation.
[21] M. Selenica,et al. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model , 2020, Journal of neuroinflammation.
[22] A. D. de Bem,et al. High Cholesterol Diet Exacerbates Blood-Brain Barrier Disruption in LDLr–/– Mice: Impact on Cognitive Function , 2020, Journal of Alzheimer's disease : JAD.
[23] E. S. Abdel-Reheim,et al. Evaluation of insulin resistance induced brain tissue dysfunction in obese dams and their neonates: Role of ipriflavone amelioration. , 2020, Combinatorial chemistry & high throughput screening.
[24] D. Burrin,et al. Neurodegeneration in juvenile Iberian pigs with diet-induced non-alcoholic fatty liver disease. , 2020, American journal of physiology. Endocrinology and metabolism.
[25] Shu Zheng,et al. Application of exosomes as liquid biopsy in clinical diagnosis , 2020, Signal Transduction and Targeted Therapy.
[26] M. Nagarkatti,et al. Lipocalin 2 induces neuroinflammation and blood-brain barrier dysfunction through liver-brain axis in murine model of nonalcoholic steatohepatitis , 2020, Journal of Neuroinflammation.
[27] S. Caprio,et al. Intrahepatic fat, irrespective of ethnicity, is associated with reduced endogenous insulin clearance and hepatic insulin resistance in obese youths: a cross-sectional and longitudinal study from the Yale Pediatric NAFLD cohort. , 2020, Diabetes, obesity & metabolism.
[28] R. Karbalaei,et al. Showing NAFLD, as a key connector disease between Alzheimer’s disease and diabetes via analysis of systems biology , 2020, Gastroenterology and hepatology from bed to bench.
[29] Y. Tachibana,et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation , 2019, Nature Communications.
[30] R. Loomba,et al. The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis Caused by NASH , 2019, Hepatology.
[31] Jonathan D. Smith,et al. HDL Flux is Higher in Patients with Nonalcoholic Fatty Liver Disease. , 2019, American journal of physiology. Endocrinology and metabolism.
[32] M. Watt,et al. The liver as an endocrine organ - linking NAFLD and insulin resistance. , 2019, Endocrine reviews.
[33] S. Hasselbalch,et al. Ageing as a risk factor for neurodegenerative disease , 2019, Nature Reviews Neurology.
[34] A. Beiser,et al. NON-ALCOHOLIC FATTY LIVER DISEASE, LIVER FIBROSIS SCORE AND COGNITIVE FUNCTION IN MIDDLE-AGED ADULTS: THE FRAMINGHAM STUDY , 2019, Alzheimer's & Dementia.
[35] Xianlin Han,et al. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers , 2019, JAMA network open.
[36] B. Miller,et al. Association of Early-Onset Alzheimer Disease With Elevated Low-density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. , 2019, JAMA neurology.
[37] F. Lesage,et al. Non-Alcoholic Fatty Liver Disease, and the Underlying Altered Fatty Acid Metabolism, Reveals Brain Hypoperfusion and Contributes to the Cognitive Decline in APP/PS1 Mice , 2019, Metabolites.
[38] R. Takahashi,et al. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice , 2019, International journal of molecular sciences.
[39] Silvia Maioli,et al. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer’s disease: Potential novel targets for treatment , 2019, The Journal of Steroid Biochemistry and Molecular Biology.
[40] T. Mocan,et al. Extracellular Vesicles in Liver Diseases: Diagnostic, Prognostic, and Therapeutic Application , 2019, Seminars in Liver Disease.
[41] Nicola J. Ray,et al. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis , 2019, Ageing Research Reviews.
[42] D. Belsham,et al. Tumour necrosis factor α induces neuroinflammation and insulin resistance in immortalised hypothalamic neurones through independent pathways , 2019, Journal of neuroendocrinology.
[43] G. Svegliati-Baroni,et al. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH , 2019, Transplantation.
[44] F. Cubero,et al. Extracellular vesicles in liver disease and beyond , 2018, World journal of gastroenterology.
[45] M. Manns,et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.
[46] K. Daffner,et al. Dementia. , 2018, The American journal of medicine.
[47] H. Reeves,et al. Liquid biopsy for liver diseases , 2018, Gut.
[48] E. Yang,et al. Relationship between Liver Pathology and Disease Progression in a Murine Model of Amyotrophic Lateral Sclerosis , 2018, Neurodegenerative Diseases.
[49] V. Felipo,et al. Histological Features of Cerebellar Neuropathology in Patients With Alcoholic and Nonalcoholic Steatohepatitis , 2018, Journal of neuropathology and experimental neurology.
[50] Ming Lu,et al. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease , 2018, Journal of Neuroinflammation.
[51] Z. Niu,et al. Serum retinol binding protein 4 and galectin-3 binding protein as novel markers for postmenopausal nonalcoholic fatty liver disease. , 2018, Clinical biochemistry.
[52] M. Altamimi,et al. Could Autism Be Associated With Nutritional Status in the Palestinian population? The Outcomes of the Palestinian Micronutrient Survey , 2018, Nutrition and metabolic insights.
[53] A. Feldstein,et al. Triggering and resolution of inflammation in NASH , 2018, Nature Reviews Gastroenterology & Hepatology.
[54] F. Schick,et al. The hepatokines fetuin-A and fetuin-B are upregulated in the state of hepatic steatosis and may differently impact on glucose homeostasis in humans. , 2018, American journal of physiology. Endocrinology and metabolism.
[55] W. Freeman,et al. Insulin-like growth factor receptor signaling regulates working memory, mitochondrial metabolism, and amyloid-β uptake in astrocytes , 2018, Molecular metabolism.
[56] S. Craft,et al. Triglycerides cross the blood–brain barrier and induce central leptin and insulin receptor resistance , 2017, International Journal of Obesity.
[57] R. Vasan,et al. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study , 2018, JAMA neurology.
[58] A. Holmgren,et al. Redox Signaling Mediated by Thioredoxin and Glutathione Systems in the Central Nervous System. , 2017, Antioxidants & redox signaling.
[59] N. Chattipakorn,et al. SGLT2‐inhibitor and DPP‐4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD‐induced obese rats , 2017, Toxicology and applied pharmacology.
[60] Miguel López,et al. Brain Ceramide Metabolism in the Control of Energy Balance , 2017, Front. Physiol..
[61] G. Reiser,et al. Brain energy metabolism spurns fatty acids as fuel due to their inherent mitotoxicity and potential capacity to unleash neurodegeneration , 2017, Neurochemistry International.
[62] S. Mukhopadhyay,et al. Palmitate induced Fetuin-A secretion from pancreatic β-cells adversely affects its function and elicits inflammation. , 2017, Biochemical and biophysical research communications.
[63] N. Stefan,et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease , 2017, Molecular Metabolism.
[64] G. Gores,et al. TRAIL deletion prevents liver inflammation but not adipose tissue inflammation during murine diet‐induced obesity , 2017, Hepatology communications.
[65] M. Watt,et al. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance , 2017, Nature Reviews Endocrinology.
[66] S. Friedman,et al. Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.
[67] W. Ling,et al. Retinol Binding Protein-4 Levels and Non-alcoholic Fatty Liver Disease: A community-based cross-sectional study , 2017, Scientific Reports.
[68] Jun Li,et al. Emerging role of exosomes in liver physiology and pathology , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.
[69] J. Rutledge,et al. Triglyceride-rich lipoprotein lipolysis products increase blood-brain barrier transfer coefficient and induce astrocyte lipid droplets and cell stress. , 2017, American journal of physiology. Cell physiology.
[70] A. Ahmadiani,et al. Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment , 2017, CNS neuroscience & therapeutics.
[71] M. Bredella,et al. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease , 2017, Clinical and Translational Gastroenterology.
[72] Zhi-Sheng Jiang,et al. Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression , 2016, Molecular medicine reports.
[73] R. Swerdlow,et al. Mitochondria, Cybrids, Aging, and Alzheimer's Disease. , 2017, Progress in molecular biology and translational science.
[74] R. Carr,et al. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. , 2016, Gastroenterology clinics of North America.
[75] M. Beekman,et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice , 2016, Scientific Reports.
[76] S. Glaser,et al. Exosomes in liver pathology. , 2016, Journal of hepatology.
[77] M. Orešič,et al. Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .
[78] G. Gores,et al. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. , 2016, Gastroenterology.
[79] Jeanne M. Clark,et al. Nonalcoholic fatty liver disease is associated with cognitive function in adults , 2016, Neurology.
[80] G. Gores,et al. Mixed lineage kinase 3 mediates release of C‐X‐C motif ligand 10–bearing chemotactic extracellular vesicles from lipotoxic hepatocytes , 2016, Hepatology.
[81] R. Coffman,et al. Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. , 2016, The Journal of clinical investigation.
[82] S. Mclennan,et al. Molecular Sciences Extracellular Vesicles: a New Frontier in Biomarker Discovery for Non-alcoholic Fatty Liver Disease , 2022 .
[83] M. Yin,et al. Hepatocytes release ceramide-enriched pro-inflammatory extracellular vesicles in an IRE1α-dependent manner[S] , 2016, Journal of Lipid Research.
[84] Leon E. Toussaint,et al. Non-alcoholic fatty liver disease induces signs of Alzheimer’s disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model , 2016, Journal of Neuroinflammation.
[85] P. Chaurand,et al. Aberrant Lipid Metabolism in the Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model of Alzheimer's Disease. , 2015, Cell stem cell.
[86] P. Acton,et al. Peripheral Administration of Tumor Necrosis Factor-Alpha Induces Neuroinflammation and Sickness but Not Depressive-Like Behavior in Mice , 2015, BioMed research international.
[87] H. Neumann,et al. CXCL10 Triggers Early Microglial Activation in the Cuprizone Model , 2015, The Journal of Immunology.
[88] G. Gores,et al. Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis , 2014, Cellular and molecular gastroenterology and hepatology.
[89] A. Wree,et al. Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease , 2014, PloS one.
[90] J. Trepanowski,et al. Fetuin-A: a novel link between obesity and related complications , 2014, International Journal of Obesity.
[91] A. Wree,et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD , 2014, Journal of Molecular Medicine.
[92] S. M. de la Monte,et al. Brain metabolic dysfunction at the core of Alzheimer's disease. , 2014, Biochemical pharmacology.
[93] T. Saibara,et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients , 2014, Journal of Gastroenterology.
[94] M. Synofzik,et al. Evidence for altered transport of insulin across the blood–brain barrier in insulin-resistant humans , 2014, Acta Diabetologica.
[95] Hulun Li,et al. Accumulation of natural killer cells in ischemic brain tissues and the chemotactic effect of IP-10 , 2014, Journal of Neuroinflammation.
[96] Q. Anstee,et al. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging , 2013, Frontline Gastroenterology.
[97] R. Schwabe,et al. Fate-tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its etiology , 2013, Nature Communications.
[98] E. Fisher,et al. Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease , 2013, Seminars in Liver Disease.
[99] Andreas Meisel,et al. Sugar for the brain: the role of glucose in physiological and pathological brain function , 2013, Trends in Neurosciences.
[100] J. Loeffler,et al. Fatting the brain: a brief of recent research , 2013, Front. Cell. Neurosci..
[101] A. Goustin,et al. Ahsg-fetuin blocks the metabolic arm of insulin action through its interaction with the 95-kD β-subunit of the insulin receptor. , 2013, Cellular signalling.
[102] Laura J. Dixon,et al. Kupffer cells in the liver. , 2013, Comprehensive Physiology.
[103] N. Chattipakorn,et al. DPP4‐inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high‐fat diet consumption , 2013, The European journal of neuroscience.
[104] V. Adam,et al. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. , 2012, Oncology letters.
[105] R. Palmiter,et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. , 2012, Antioxidants & redox signaling.
[106] J. Kaye,et al. Dyslipidemia and Blood-Brain Barrier Integrity in Alzheimer's Disease , 2012, Current gerontology and geriatrics research.
[107] Eduardo D. Martín,et al. IRS-2 Deficiency Impairs NMDA Receptor-Dependent Long-term Potentiation , 2011, Cerebral cortex.
[108] D. Ghareeb,et al. Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction , 2011, Metabolic Brain Disease.
[109] J. Wands,et al. Weight loss amelioration of non‐alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.
[110] A. Dolganiuc,et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells , 2011, Hepatology.
[111] G. Reiser,et al. Non‐esterified polyunsaturated fatty acids distinctly modulate the mitochondrial and cellular ROS production in normoxia and hypoxia , 2011, Journal of neurochemistry.
[112] B. Platt,et al. Susceptibility to diet-induced obesity and glucose intolerance in the APPSWE/PSEN1A246E mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein , 2011, Diabetologia.
[113] Joel Z Stengel,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.
[114] J. Féher,et al. Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker , 2010, PloS one.
[115] Martin D. Brand,et al. The sites and topology of mitochondrial superoxide production , 2010, Experimental Gerontology.
[116] B. Garner. Lipids and Alzheimer's disease. , 2010, Biochimica et biophysica acta.
[117] L. Ferrucci,et al. Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.
[118] Rosemary O’Connor,et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling , 2010, Neurobiology of Aging.
[119] J. Wands,et al. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. , 2010, Journal of Alzheimer's disease : JAD.
[120] L. Lesmana,et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non‐alcoholic steatohepatitis , 2009, Journal of digestive diseases.
[121] M. Swain,et al. Cerebral Microglia Recruit Monocytes into the Brain in Response to Tumor Necrosis Factorα Signaling during Peripheral Organ Inflammation , 2009, The Journal of Neuroscience.
[122] Z Walker,et al. Microglial activation and amyloid deposition in mild cognitive impairment , 2009, Neurology.
[123] J. Wands,et al. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. , 2009, Journal of Alzheimer's disease : JAD.
[124] M. Mahmoudi,et al. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. , 2009, Recent patents on inflammation & allergy drug discovery.
[125] A. Passaro,et al. Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia , 2008, Journal of the Neurological Sciences.
[126] H. Scheich,et al. Overexpression of human apolipoprotein B-100 induces severe neurodegeneration in transgenic mice. , 2008, Journal of proteome research.
[127] K. Xiang,et al. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. , 2008, Diabetes research and clinical practice.
[128] B. S. Mohammed,et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. , 2008, Gastroenterology.
[129] V. Haroutunian,et al. Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer’s Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer’s Disease? , 2007, Neurochemical Research.
[130] Y. Le Marchand-Brustel,et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. , 2007, Endocrinology.
[131] G. Wilcock,et al. The metabolic syndrome and Alzheimer disease. , 2007, Archives of neurology.
[132] S. Summers,et al. Ceramides in insulin resistance and lipotoxicity. , 2006, Progress in lipid research.
[133] E. Parks,et al. Spillover of dietary fatty acids and use of serum nonesterified fatty acids for the synthesis of VLDL-triacylglycerol under two different feeding regimens. , 2005, Diabetes.
[134] J. Wands,et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.
[135] I. Santana,et al. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Aβ toxicity , 2004, Journal of neurochemistry.
[136] Y. Masui,et al. Functional and morphometric study of the liver in motor neuron disease , 2004, Journal of Neurology.
[137] J. Kushner,et al. Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation , 2003, The Journal of Neuroscience.
[138] I A Silver,et al. Tissue oxygen tension and brain sensitivity to hypoxia. , 2001, Respiration physiology.
[139] H. Lei,et al. Tumour necrosis factor-α causes an increase in blood-brain barrier permeability during sepsis , 2001 .
[140] H. Lei,et al. Tumour necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. , 2001, Journal of medical microbiology.
[141] R. Swerdlow,et al. Alzheimer's disease cybrids replicate β‐amyloid abnormalities through cell death pathways , 2000 .
[142] G. Brown,et al. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. , 1997, Physiological reviews.
[143] W. Banks,et al. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.
[144] D. Porte,et al. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats , 1990, Peptides.
[145] K. Shirai,et al. Existence of lipoprotein lipase in rat brain microvessels. , 1986, The Tohoku journal of experimental medicine.
[146] A. Bernsmeier,et al. [The glucose consumption of the brain & its dependence on the liver]. , 1958, Archiv fur Psychiatrie und Nervenkrankheiten, vereinigt mit Zeitschrift fur die gesamte Neurologie und Psychiatrie.
[147] D. Harman. Aging: a theory based on free radical and radiation chemistry. , 1956, Journal of gerontology.